{"name":"Cleave Therapeutics, Inc.","slug":"cleave-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CB-5339","genericName":"CB-5339","slug":"cb-5339","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CB-5339","genericName":"CB-5339","slug":"cb-5339","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdFNWNDlpakQwZjB0dktma0tNeXpiZHRJOUg5dDEwQm9hc3QtZ0xaclAxTTdTSFp6dS1UYV9TNkpNZW1iVUdkV3FReFVGeDh2RXhCMTl5WHdYWlFSQUFoMUxrZU9FQlVMVnE1SENRMlBpeHExMEN3dWVURFR1MjVnWFQzNi1xc2ZMdk5Ocldpa1FCVXdRS3NHUHdlOVVuRGlValNiM3RR?oc=5","date":"2026-03-25","type":"deal","source":"The Business Journals","summary":"From failure to hit to a $6.7 billion buyout: Terns Pharma gets big offer from Merck - The Business Journals","headline":"From failure to hit to a $6.7 billion buyout: Terns Pharma gets big offer from Merck","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"globenewswire.com","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - globenewswire.com","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNR2VzcVJEN1NiSXh3WHR2Zi1GeHVOa252YnJqcWVjTEkyUWJiSWdHR1N2UlhTX3ZDZGRjRktMYkJqT3pUU3dVMzIydGhUOURkb0xYMGlEcGtobk1MLWtKSFlub043RXJuWmZRakVnRmhXMVM1TjBVRVRnYVBqNFdWaTJrNVZtUTBBSVhGcm5MUG0?oc=5","date":"2026-01-20","type":"pipeline","source":"PharmTech.com","summary":"Proteasomes: A Novel Approach to Target the Immune System - PharmTech.com","headline":"Proteasomes: A Novel Approach to Target the Immune System","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxONFVKVnlORi1vWXdsSUVzcXlvNW5VTEZfLV9xM1lUOTVUdDNrWXI1Z3ZpUFV1MHpkT3RxS1doUW1hd3RtVUVqdkFoZk9vSVlzSnI2SVpfZUphZmdNdWdaS2dXeG0xTTYtZmNmeV93TlJsR1dndjZnLUxVOGQ0aFpiSnVFa2FkelBPNXd0QWZ6WG1XS1Uz?oc=5","date":"2025-02-26","type":"pipeline","source":"MedCity News","summary":"Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing - MedCity News","headline":"Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcUpnSk5wUndITEp1TjNtZUlTQUF5cmVFRllXMmRiYTlTaHR5bTdpQnFKT1BJcGwtaUpmZXJzZXhlSHpmblI3akxvbm90NWNURDlIbnIyeUhnNG9HZzdqTjltNWdzek5ibEJ4ZWJ1Tm83Q3Q2T1FmTU50ZWJ4UUl2TGtsS01qRzJVbGV3?oc=5","date":"2024-11-26","type":"pipeline","source":"Life Science Leader","summary":"Companies To Watch: Terns Pharmaceuticals - Life Science Leader","headline":"Companies To Watch: Terns Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxONjdCOVdxa3ZTYm1SblV1aXdfMUVZb3Rkd0VLOEVYYUQzZS1IaTk3dlBxcEpvX2VMZENZbnJOaTFKeFRXNXlkSFBpU0Y1WGtFZU9oemt3WW1VWW11eW5tNTJ6VWFrWkEwamJWX0JFVVJvM1M2eFo4STNQd1Azb3ZHRU5haVlnZzhBOXc?oc=5","date":"2024-02-09","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Ex-CRISPR Tx CMO lands at Takeda - Fierce Biotech","headline":"Chutes & Ladders—Ex-CRISPR Tx CMO lands at Takeda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQRUN2aE1sVmdsQ3g3Q2t1cmlHYnlKRmVMRTdwRkhIeS1GdWhtd0RncUt5NUZMNHJ1RU5CNkhTVlduWnpxVXliS25JMUlQbnY2clR6N19kVWp3eW5qZ0JCZTVzNm4yTlpFMHBTX0tSa2Z6dVlnQW9hMnM5engwc1RqQUYtamRaQjUtekpvRVBKNGZ6cmFGT1pXM09FcEhlRmwzRVRfSTlNRjdVcXVaOHNNdzI1dzk?oc=5","date":"2023-07-21","type":"deal","source":"Contract Pharma","summary":"CASI Acquires Rights to Cleave Therapeutics’ VCP/P97 Inhibitor CB-5339 - Contract Pharma","headline":"CASI Acquires Rights to Cleave Therapeutics’ VCP/P97 Inhibitor CB-5339","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOaU42RHpVcjZTUmxWVE03TjM5cC1LX19DTWswb3NxcWdRdklsYXBMR1ZtWHhLQUNES091RlVaR3ppOUN6ak9nUVM3d3ZHZkMwUzh6ZGlaZzRfZnlscXlWeFk0QjRXV1pELUpNMW9GRVdSb0JjY0tITEVMdmtxQ254aUZtSGZrazlmcjd6QmY0SzhMMFJGcXhYOGVWZWxmWUJUdXlYS1Iyck96SThzNUNOcXZLbnNuSTBzNjBCMW1kT1N5WjB0UFpIS2JKRy1Uekd1RUJHTDg5ZThpa19WUGdRWWJTQkZsYk83Rm9paFE1RXI1U2xPLUFVczdvSzZsUQ?oc=5","date":"2023-07-20","type":"deal","source":"PR Newswire","summary":"CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 - PR Newswire","headline":"CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOX0lOLWxPUTZsYTVmX1NMLVR4UGpxazZ4NXlFTzBTZndvNkpSWXhTcXI0UUxHVUlhTEh2NkJ2Zk5iYXh0ZGF5ZGE4LXF6aWVzdVUzM2hhMjlzVUhTQnhHRVB6SGYyOHpSdXlpSDVPbWhWVk1DOG9aOUtUbVFQVnY1TEVrYWZOQUs0cFRyMmt2dmZoN1k?oc=5","date":"2023-06-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Eikon Therapeutics bag $106m to fund eager acquisitions - Pharmaceutical Technology","headline":"Eikon Therapeutics bag $106m to fund eager acquisitions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNbVJJUGU4WTI5bXpydUpUY1pidWlNdTZrSHdGelRsNzh6cFpmakRpaFNKcjJUc1ducWlpTFlWU2VBeVJadWVvUFVGOFEyb0RPOGhLa2dWUVNKYTFoRTc1R3o5cVRfRklxN1FLNzdJT0JEcDVjWFltS1NHVks2MXh5eE9SaHNLVUVGa2FfeG9zODRNMmhqSThIeHBaUEdoM29QeDRkTVV4ZHBNdkxzUTlnZVl5ZW1TMHdtUGE2cEpIa2ZJX21ZTDV4dURNbVdjNjlUZlF2QlNKM3hCc0EyUUMwOGlBX1VjV2FyaVpfd040OXlNekNXLUdRTmluUTlteFBycUE?oc=5","date":"2023-06-01","type":"deal","source":"Business Wire","summary":"Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline - Business Wire","headline":"Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxOV0FiLXBsT2ZXNVVBejFZUVdVNmFJODlIMzJQN01uVHE0MUpZTWwxV2h2UWo3Sk52aDFmUzY2aW1Lb1FSN0RNaGxmR0JkbTMxcXp6a3hhMHNZR2VUWGl0WkpVeXJEV3djUURHVVRDVUNtc2JwRC12MFpFX0ZqcWZHQlFoRGFNUk9VdkRKOUk1TW9nbmotQTNVcE54ZHJ5VklFeHhLTHFEZ053b1BJZ3N3c0RiYXhhenFTTkd5QTBVTUJwbnhuSjl4TXNjN0JabXVwRGRzSWFpc2JjM3lrcS1hUDZrMWVnalFKb0tOMF9OVGhFWXN5di10MldPdEoxTlV5V2lV?oc=5","date":"2021-03-08","type":"deal","source":"PR Newswire","summary":"Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region - PR Newswire","headline":"Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQUTBESl9GNzVjRmtySjBTc0ZpeVFyUnlrdEZrdm9lbE53a3FSR0NzcTNaWVFkS3BOYWV5ZWMtNEdsYkU2WDV0UmdtYUxPZkw0XzR1cTh5TjZyXzZTS1dzb0JBMFRtcTByNTlEZjdaRU8wLUlIaTR4N1A2MzFZTmdNWTR4OWlxS3dFLVozNVJVY2FaQ3duRFo4X3RwTWtFRVBsMjg1ZmlrWEFqSEtMNFBJR0Q4OWwwaHMwSGlnT0FFOUp6eEhWNTN1Q3Fldk44QQ?oc=5","date":"2019-08-06","type":"pipeline","source":"BioSpace","summary":"Cleave Therapeutics Appoints Amy Burroughs Chief Executive Officer and Completes $12 Million Equity Financing - BioSpace","headline":"Cleave Therapeutics Appoints Amy Burroughs Chief Executive Officer and Completes $12 Million Equity Financing","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}